ReviewCancer metastasis reviews2023
Carcinoma of unknown primary (CUP): an update for histopathologists.
Review in Cancer metastasis reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Soft multiclass feature augmented deep learning to predict tumor origins using cytology or histology whole slide images.NPJ digital medicine · 2026Article
- Breaking New Ground in Cervical Metastatic Carcinoma of Unknown Primary: Neoadjuvant Immunochemotherapy's Pathologic Regression and Survival Advantage.Annals of surgical oncology · 2026Article
- Cytokeratin profile supports developmental origin of cerebellopontine angle epidermoid cysts.Brain & spine · 2026Article
- Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment.Nature reviews. Clinical oncology · 2025Review
- Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine.MedComm · 2025Review
- Skeletal Muscle Density as a Predictor of Prognosis and Physical Reserve in Patients with Cancer of Unknown Primary.Journal of clinical medicine · 2025Article
- Clinical characteristics and survival analysis of cancer of unknown primary.Oncology letters · 2025Article
- Cancer of Unknown Primary With Squamous Cell Carcinoma Phenotype Presenting as Isolated Axillary Mass.Cureus · 2025Article
- Overcoming diagnostic pitfalls in primary gastric squamous cell carcinoma: the imperative of adequate sampling in an elderly female patient, case report.Frontiers in oncology · 2025Article
- Case Report: Palliative chemotherapy with gemcitabine and carboplatin for carcinoma of unknown primary with metastasis in a cat.Frontiers in veterinary science · 2025Article
- Epidemiologic, histopathological, and prognostic analysis of cancer of unknown primary in an Iranian population.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoma of unknown primary (CUP) is a heterogeneous group of metastatic cancers in which the site of origin is not identifiable. These carcinomas have a poor outcome due to their late presentation with metastatic disease, difficulty in identifying the origin and delay in treatment. The aim of the pathologist is to broadly classify and subtype the cancer and, where possible, to confirm the likely primary site as this information best predicts patient outcome and guides treatment. In this review, we provide histopathologists with diagnostic practice points which contribute to identifying the primary origin in such cases. We present the current clinical evaluation and management from the point of view of the oncologist. We discuss the role of the pathologist in the diagnostic pathway including the control of pre-analytical conditions, assessment of sample adequacy, diagnosis of cancer including diagnostic pitfalls, and evaluation of prognostic and predictive markers. An integrated diagnostic report is ideal in cases of CUP, with results discussed at a forum such as a molecular tumour board and matched with targeted treatment. This highly specialized evolving area ultimately leads to personalized oncology and potentially improved outcomes for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.